SciELO - Scientific Electronic Library Online

 
vol.99 número2Cirurgia valvar mitral e da comunicação interatrial: abordagem minimamente invasiva ou por esternotomiaImplante por cateter de bioprótese valvar para tratamento da estenose aórtica: experiência de três anos índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

Links relacionados

Compartilhar


Arquivos Brasileiros de Cardiologia

versão impressa ISSN 0066-782X

Resumo

MARTINS, Gerez Fernandes et al. Trimetazidine and inflammatory response in coronary artery bypass grafting. Arq. Bras. Cardiol. [online]. 2012, vol.99, n.2, pp.688-696.  Epub 13-Jul-2012. ISSN 0066-782X.  http://dx.doi.org/10.1590/S0066-782X2012005000066.

BACKGROUND: Organic inflammatory response is a pathophysiological mechanism present at every coronary artery bypass grafting with extracorporeal circulation (CABG-ECC), the release of inflammatory mediators being one of its defense mechanisms. OBJECTIVE: To assess, in a prospective double-blind randomized and placebo-controlled study, the effects of trimetazidine (Tmz) on the inflammatory response, by using the variation in interleukins 6 and 8, TNF-α, complements C3 and C5, and highly sensitive C-reactive protein (HS-CRP) levels in the pre- and post-operative periods. METHODS: This study assessed 30 patients undergoing CABG-ECC with intermittent hypothermic cardioplegia, and having, at most, mild ventricular dysfunction. The patients were divided into two groups (placebo and Tmz), stratified by echocardiography, and received drug/placebo at the dose of 60 mg/day. Measurements were taken as follows: in the pre-operative period with no drug; on the day of surgery, corresponding to 12 to 15 days on drug/placebo; five minutes after aortic unclamping; 12 and 24 hours after surgery, for interleukins and complements; and 48 hours after surgery, for HS-CRP. RESULTS: No significant difference between the levels of interleukin 8, TNF-α, C3 and C5, and HS-CRP was observed. However, the interleukin 6 levels were significantly lower in the group treated as compared with those in the control group at all time points assessed. CONCLUSION: Trimetazidine proved to be effective only for reducing interleukin 6 in patients undergoing CABG.

Palavras-chave : Trimetazidine [administration & dosage]; inflammation; myocardial revascularization; myocardial reperfusion.

        · resumo em Português     · texto em Português | Inglês     · Português ( pdf ) | Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons